We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck (MRK) Stock Moves -0.06%: What You Should Know
Read MoreHide Full Article
Merck (MRK - Free Report) closed the most recent trading day at $78.83, moving -0.06% from the previous trading session. This move was narrower than the S&P 500's daily loss of 0.1%. Meanwhile, the Dow lost 0.47%, and the Nasdaq, a tech-heavy index, lost 0.47%.
Coming into today, shares of the pharmaceutical company had gained 7.74% in the past month. In that same time, the Medical sector gained 1.09%, while the S&P 500 gained 3.67%.
Wall Street will be looking for positivity from Merck as it approaches its next earnings report date. This is expected to be February 3, 2022. The company is expected to report EPS of $1.45, up 9.85% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $12.62 billion, up 0.84% from the prior-year quarter.
Investors should also note any recent changes to analyst estimates for Merck. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Merck is currently a Zacks Rank #3 (Hold).
Digging into valuation, Merck currently has a Forward P/E ratio of 11.47. This represents a discount compared to its industry's average Forward P/E of 12.43.
Also, we should mention that MRK has a PEG ratio of 1.73. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 109, which puts it in the top 43% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MRK in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Merck (MRK) Stock Moves -0.06%: What You Should Know
Merck (MRK - Free Report) closed the most recent trading day at $78.83, moving -0.06% from the previous trading session. This move was narrower than the S&P 500's daily loss of 0.1%. Meanwhile, the Dow lost 0.47%, and the Nasdaq, a tech-heavy index, lost 0.47%.
Coming into today, shares of the pharmaceutical company had gained 7.74% in the past month. In that same time, the Medical sector gained 1.09%, while the S&P 500 gained 3.67%.
Wall Street will be looking for positivity from Merck as it approaches its next earnings report date. This is expected to be February 3, 2022. The company is expected to report EPS of $1.45, up 9.85% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $12.62 billion, up 0.84% from the prior-year quarter.
Investors should also note any recent changes to analyst estimates for Merck. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Merck is currently a Zacks Rank #3 (Hold).
Digging into valuation, Merck currently has a Forward P/E ratio of 11.47. This represents a discount compared to its industry's average Forward P/E of 12.43.
Also, we should mention that MRK has a PEG ratio of 1.73. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 109, which puts it in the top 43% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MRK in the coming trading sessions, be sure to utilize Zacks.com.